Healthcare provider profile · identity verified

Hye Gi Shim

Internal Medicine · NEW YORK, NY · NPI 1740694991

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	404	124
Amlodipine Besylate	Amlodipine Besylate	303	105
Albuterol Sulfate Hfa	Albuterol Sulfate	182	34
Metformin Hcl	Metformin Hcl	172	49
Losartan Potassium	Losartan Potassium	163	48
Omeprazole	Omeprazole	158	49
Gabapentin	Gabapentin	145	50
Metoprolol Succinate	Metoprolol Succinate	113	35
Fluticasone Propionate	Fluticasone Propionate	107	29
Lisinopril	Lisinopril	102	34
Alendronate Sodium	Alendronate Sodium	98	21
Jardiance	Empagliflozin	93	27
Levothyroxine Sodium	Levothyroxine Sodium	91	28
Hydrochlorothiazide	Hydrochlorothiazide	89	28
Rosuvastatin Calcium	Rosuvastatin Calcium	88	27
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	68	17
Ozempic	Semaglutide	67	18
Carvedilol	Carvedilol	66	22
Duloxetine Hcl	Duloxetine Hcl	66	21
Eliquis	Apixaban	66	16
Pantoprazole Sodium	Pantoprazole Sodium	61	22
Diclofenac Sodium	Diclofenac Sodium	57	18
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	57	suppressed
Chlorthalidone	Chlorthalidone	52	17
Tamsulosin Hcl	Tamsulosin Hcl	52	18
Clopidogrel	Clopidogrel Bisulfate	48	suppressed
Montelukast Sodium	Montelukast Sodium	47	11
Novolog Flexpen	Insulin Aspart	46	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	42	suppressed
Furosemide	Furosemide	40	11
Famotidine	Famotidine	38	17
Entresto	Sacubitril/Valsartan	35	suppressed
Nifedipine Er	Nifedipine	35	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	33	13
Spironolactone	Spironolactone	32	suppressed
Farxiga	Dapagliflozin Propanediol	31	suppressed
Simvastatin	Simvastatin	30	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	29	12
Meclizine Hcl	Meclizine Hcl	27	15
Trazodone Hcl	Trazodone Hcl	27	suppressed
Rybelsus	Semaglutide	26	suppressed
Trulicity	Dulaglutide	26	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	25	suppressed
Pravastatin Sodium	Pravastatin Sodium	24	suppressed
Ezetimibe	Ezetimibe	23	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	23	suppressed
Allopurinol	Allopurinol	22	suppressed
Mirtazapine	Mirtazapine	22	suppressed
Xarelto	Rivaroxaban	22	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	21	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	21	suppressed
Pregabalin	Pregabalin	21	suppressed
Ultra-Fine Nano Pen Needle	Pen Needle, Diabetic	21	suppressed
Azelastine Hcl	Azelastine Hcl	19	suppressed
Citalopram Hbr	Citalopram Hydrobromide	19	suppressed
Lidocaine	Lidocaine	18	suppressed
Buspirone Hcl	Buspirone Hcl	17	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	16	suppressed
Vitamin D2	Ergocalciferol (Vitamin D2)	16	suppressed
Torsemide	Torsemide	15	suppressed
Incruse Ellipta	Umeclidinium Bromide	14	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	14	suppressed
Januvia	Sitagliptin Phosphate	14	suppressed
Alcohol Prep Pads	Alcohol Antiseptic Pads	13	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	13	suppressed
Creon	Lipase/Protease/Amylase	13	suppressed
Latanoprost	Latanoprost	13	suppressed
Levetiracetam	Levetiracetam	13	suppressed
Sertraline Hcl	Sertraline Hcl	13	suppressed
Tirosint	Levothyroxine Sodium	13	suppressed
Toujeo Solostar	Insulin Glargine,hum.Rec.Anlog	13	suppressed
Alcohol Swabs	Alcohol Antiseptic Pads	12	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	12	suppressed
Dulera	Mometasone/Formoterol	12	suppressed
Linzess	Linaclotide	12	suppressed
Symbicort	Budesonide/Formoterol Fumarate	12	suppressed
Ammonium Lactate	Ammonium Lactate	11	suppressed
Finasteride	Finasteride	11	suppressed
Hydrocortisone	Hydrocortisone	11	suppressed
Topiramate	Topiramate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error